CircRNA hsa-circ-0014359 promotes glioma progression by regulating miR-153/PI3K signaling-Reference-Cited by-同舟云学术

CircRNA hsa-circ-0014359 promotes glioma progression by regulating miR-153/PI3K signaling

Published:2019-03 Issue:4 Volume:510 Page:614-620
ISSN:0006-291X
Container-title:Biochemical and Biophysical Research Communications
language:en
Short-container-title:Biochemical and Biophysical Research Communications

Author:

Shi Fei^ORCID,Shi Zhonghua,Zhao Yaodong,Tian Jiwei

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry,Biophysics

Reference18 articles.

1. The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines;Shi;Neuroscience,2017

2. PI3K-mTOR pathway inhibition exhibits efficacy against high-grade glioma in clinically relevant mouse models;Lin;Clin. Canc. Res.,2017

3. The effect of chemoradiotherapy with SRC tyrosine kinase inhibitor, PP2 and temozolomide on malignant glioma cells in vitro and in vivo, cancer research and treatment;Eom;J. Korean. Canc. Assoc.,2016

4. CircRNA circHIPK3 serves as a prognostic marker to promote glioma progression by regulating miR-654/IGF2BP3 signaling;Jin;Biochem. Biophys. Res. Commun.,2018

5. Circular RNAs: a new frontier for cancer diagnosis and therapy;Zhang;J. Hematol. Oncol.,2018

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The landscape of circRNAs in gliomas temozolomide resistance: Insights into molecular pathways;Non-coding RNA Research;2024-12

2. Predicting associations between CircRNA and diseases through structure-aware graph transformer and path-integral convolution;Analytical Biochemistry;2024-09

3. Exploring the impact of circRNAs on cancer glycolysis: Insights into tumor progression and therapeutic strategies;Non-coding RNA Research;2024-09

4. A novel nanoplatform-based circCSNK1G3 affects CBX7 protein and promotes glioma cell growth;International Journal of Biological Macromolecules;2024-09

5. Circular RNAs in human diseases;MedComm;2024-09